Vyome Holdings (HIND) Assets Average (2016 - 2026)
Vyome Holdings (HIND) posted Assets Average of $9.7 million for Q2 2026, up 16.06% on a QoQ basis from $8.3 million in Q1 2026, and up 84.91% year-over-year from $5.2 million in Q2 2025.
Analysis
Vyome Holdings (HIND) Assets Average (2016 - 2026) Analysis & Trends
Vyome Holdings has reported Assets Average for 11 years, with the latest figure at $9.7 million in Q2 2026.
- On a quarterly basis, Assets Average rose 84.91% year-over-year to $9.7 million in Q2 2026; TTM through Jun 2026 was $9.7 million, a 84.91% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, down 34.59% from the prior year.
- Assets Average was $9.7 million for Q2 2026 at Vyome Holdings, up from $8.3 million in the prior quarter.
- The five-year high for Assets Average was $49.1 million in Q1 2022, with the low at $1.3 million in Q4 2024.
- Average Assets Average over 5 years is $14.0 million, with a median of $9.3 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2026: Assets Average slumped 85.61% in 2024, then jumped 490.61% in 2026.
- Over 5 years, Assets Average stood at $18.8 million in 2022, then sank by 50.86% to $9.2 million in 2023, then plunged by 85.61% to $1.3 million in 2024, then jumped by 409.15% to $6.8 million in 2025, then jumped by 42.97% to $9.7 million in 2026.
- The last three Assets Average figures came in at $9.7 million (Q2 2026), $8.3 million (Q1 2026), and $6.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | 9.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.68 Mn |
| Mar 31, 2026 | 8.34 Mn |
| Dec 31, 2025 | 6.77 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Jun 30, 2025 | 5.24 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Mar 31, 2024 | 9.45 Mn |
| Dec 31, 2023 | 9.25 Mn |
| Sep 30, 2023 | 9.84 Mn |
| Jun 30, 2023 | 14.10 Mn |
| Mar 31, 2023 | 13.75 Mn |
| Dec 31, 2022 | 18.81 Mn |
| Sep 30, 2022 | 33.42 Mn |
| Jun 30, 2022 | 42.99 Mn |
| Mar 31, 2022 | 49.08 Mn |
| Dec 31, 2021 | 71.66 Mn |
| Sep 30, 2021 | 105.40 Mn |